Leronlimab increases PD-L1 expression on circulating tumor cells, potentially converting "cold" tumors to "hot" ones, enhancing immune response in metastatic triple-negative breast cancer.

In a study, 88% of patients receiving leronlimab showed increased PD-L1 levels, suggesting improved responsiveness to immune checkpoint inhibitors.

Leronlimab's mechanism may offer new treatment options for solid tumors with low PD-L1 levels, traditionally resistant to immunotherapy.

Further studies are needed to confirm leronlimab's potential in transforming tumor environments and improving outcomes in solid tumor oncology

Read in full

https://www.curetoday.com/view/leronlimab-lin...ast-cancer